Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23957498 | 0.86 | MAPT (0.48) | LMNAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL24581224 | 0.78 | MAPT (0.45) | LMNAALDH1A1L3MBTL1MAPTHRH3 | |
| SCHEMBL24581205 | 0.74 | LMNA (0.42) | LMNAALDH1A1L3MBTL1MAPTHRH3 | |
| SCHEMBL24581234 | 0.74 | LMNA (0.42) | LMNAALDH1A1L3MBTL1MAPTHRH3 | |
| SCHEMBL24564677 | 0.73 | MEN1 (0.47) | LMNAALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL24564651 | 0.73 | ALDH1A1 (0.64) | LMNAALDH1A1SMN1; SMN2TSHRKMT2A | |
| SCHEMBL24564689 | 0.73 | ALDH1A1 (0.45) | LMNAALDH1A1SMN1; SMN2TSHRMEN1 | |
| SCHEMBL24564690 | 0.73 | ALDH1A1 (0.45) | LMNAALDH1A1SMN1; SMN2TSHRMEN1 | |
| SCHEMBL24564698 | 0.73 | ALDH1A1 (0.45) | LMNAALDH1A1SMN1; SMN2TSHRMEN1 | |
| SCHEMBL29697162 | 0.73 | ALDH1A1 (0.45) | LMNAALDH1A1SMN1; SMN2TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204471-A1 | Compounds and Methods for Treating Autoimmune Disorders by Targeting HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204471-A1 | Compounds and Methods for Treating Autoimmune Disorders by Targeting HLA-DQ2 | HLA-DRB1, CD74, HLA-B | LMNA 3860/4885ALDH1A1 3804/4885SMN1; SMN2 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.